Amgen's Q1 2024: Top-Line Triumphs Meet Margin Mechanics in a Horizon-Heavy Quarter

Top-line momentum powered by Horizon and a diverse portfolio

Amgen reported a first-quarter 2024 revenue of about $7.4 billion, up roughly 22% from the prior year. The beat on the topline comes with a narrative: product sales rose in tandem with volume, lifting growth to 25% on unit levels in the quarter. A meaningful contributor here is the Horizon Therapeutics acquisition, which delivered about $914 million in sales in the period.

Geography mattered as well: U.S. volumes climbed 29%, while ex-U.S. volumes rose 17%. Ten products posted at least double-digit volume growth in Q1, including emblematic drivers like Repatha (evolocumab), TEZSPIRE (tezepelumab-ekko), EVENITY (romosozumab-aqqg), BLINCYTO (blinatumomab), and TAVNEOS (avacopan). The mix shift toward these portfolio accelerants helped offset ongoing macro headwinds and underscored Amgen’s mix-shift strategy—more high-growth franchises, fewer over-reliant legacy lines.

In practical terms, the revenue trajectory gives Amgen a talking point for any earnings-call questions about the sustainability of growth, and it provides a plausible rebuttal to the notion that Horizon is merely a one-time uplift. It isn’t a free punchline; it’s the stage direction for a multi-product, multi-market playbook that Amgen has been cultivating.

Profitability in the spotlight: GAAP EPS takes a hit while revenue stays buoyant

The headline numbers on earnings per share tell a more nuanced story. GAAP loss per share came in at $0.21 for the quarter, versus GAAP earnings per share of $5.28 in the first quarter of 2023. The swing is explained by factors including a mark-to-market loss on the BeiGene equity investment and higher operating costs, notably the amortization expense associated with Horizon-acquired assets and incremental Horizon-related expenses. The net effect is a mismatch between the booming top line and the direction of GAAP profitability.

On the operating side, GAAP operating income declined from about $1.9 billion to roughly $1.0 billion, and GAAP operating margin compressed by about 19 percentage points to 13.9%. The margin compression reflects the amortization and integration costs tied to Horizon, along with other operating expenses that accompany a large acquisition ecosystem shift.

Analysts will inevitably weigh the EPS consensus against the revenue strength. The contrast—a growing revenue base paired with a negative GAAP EPS—puts focus on the quality and sustainability of earnings, beyond the leverage of Horizon’s contribution. It’s the classic “growth engine with a caveat” moment, where investors must parse between one-time or front-loaded costs and ongoing profitability drivers.

What this signals for Amgen and its peers

The Horizon acquisition has clearly shifted Amgen’s growth profile. If the current trajectory persists, the company may be able to sustain higher top-line growth than in a more HRP-driven period, aided by established performers and a handful of high-potential launches. Yet, the near-term margin and EPS dynamics suggest investors should expect a balancing act: continued revenue expansion on the top line, with ongoing non-operating or non-cash considerations that temper GAAP profitability.

For sector peers, Amgen’s experience in integrating Horizon could become a reference point for how large acquisitions are priced into earnings narratives. If the integration yields synergies and accelerates adoption of key products—especially those with strong U.S. and international growth profiles—other biopharma players might be inclined to pursue complementary assets that diversify revenue streams rather than hinge on a single blockbuster. The backdrop remains a market where EPS consensus will be sensitive to one-time costs, amortization, and the pace at which pipeline products move from clinical validation to peak-revenue reality.

Risks to watch include the BeiGene stake and any subsequent mark-to-market revisions, as well as the usual externalities—pricing dynamics, payer negotiations, and regulatory tempo. Still, the quarter’s topline resilience offers a case study in how portfolio breadth and strategic acquisitions can reshape a company’s narrative, even when GAAP metrics momentarily misalign with revenue momentum.

Takeaways and what to monitor next

• Revenue trajectory remains solid, with a diversified product mix and Horizon-driven tailwinds.
• EPS figures under GAAP reveal the cost of growth; non-GAAP metrics (if disclosed) could tell a different, more accrual-friendly story.
• Analysts will weigh EPS consensus against a higher amortization burden and integration costs, while watching for any guidance shifts tied to the Horizon portfolio.
• The breadth of products delivering double-digit volume growth suggests resilience beyond the core franchises; investors may look to sustained demand signals and pricing dynamics across U.S. and international markets.

Conclusion: Growth persists, but the margin puzzle remains

Amgen’s Q1 2024 results present a two-act performance: a vivid top-line performance underpinned by a broadened product set and the Horizon acquisition, paired with a margin narrative that warns of costs-to-build and amortization drag. The company’s ability to translate this revenue strength into durable earnings growth will hinge on how quickly Horizon’s assets mature into sustainable profit streams and how the rest of the portfolio absorbs the integration costs. For AMGN and its sector peers, the message is less about the headline numbers and more about the quality of runway—how the pipeline, regional growth, and portfolio mix translate into EPS durability in an evolving health-care pricing environment.